Cargando…

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status

BACKGROUND: Pathological stage IB-IIIA lung adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation (Mt) has a high recurrence rate even after complete resection. However, there have been few reports on the risk factors for Mt recurrence. This study aimed to analyze the clinicopathol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isaka, Tetsuya, Ito, Hiroyuki, Yokose, Tomoyuki, Saito, Haruhiro, Adachi, Hiroyuki, Murakami, Kotaro, Miura, Jun, Kikunishi, Noritake, Rino, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463865/ https://www.ncbi.nlm.nih.gov/pubmed/36085020 http://dx.doi.org/10.1186/s12885-022-10057-w

Ejemplares similares

Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1–N2 epidermal growth factor receptor mutant lung adenocarcinoma
por: Isaka, Tetsuya, et al.
Publicado: (2023)

Preoperative predictors for recurrence sites associated with poor post-recurrence survival after surgery of non-small cell lung cancer: a multicenter study
por: Isaka, Tetsuya, et al.
Publicado: (2023)

Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery
por: Isaka, Tetsuya, et al.
Publicado: (2018)

Wedge resection vs. segmentectomy for lung cancer measuring ≤ 2 cm with consolidation tumor ratio > 0.25
por: Isaka, Tetsuya, et al.
Publicado: (2023)

Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR
por: Isaka, Tetsuya, et al.
Publicado: (2021)

Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
por: Murakami, Shuji, et al.
Publicado: (2022)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

Left lower lobectomy without pericardial reconstruction in a patient with a congenital pericardium defect
por: Miura, Jun, et al.
Publicado: (2023)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer
por: Nishii, Teppei, et al.
Publicado: (2014)

Radiological unilateral pleuroparenchymal fibroelastosis as a notable late complication after lung cancer surgery: incidence and perioperative associated factors
por: Inafuku, Kenji, et al.
Publicado: (2022)

Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next‐generation sequencing technique
por: Manabe, Saki, et al.
Publicado: (2020)

The management of postoperative recurrence of non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation: what is the best way?
por: Adachi, Hiroyuki, et al.
Publicado: (2022)

Plexiform schwannoma involving the trachea and recurrent laryngeal nerve: a case report
por: Nagata, Masashi, et al.
Publicado: (2015)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
por: Isaka, Tetsuya, et al.
Publicado: (2015)

Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing
por: Murakami, Shuji, et al.
Publicado: (2021)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples
por: Nemoto, Daiji, et al.
Publicado: (2020)

Case-Control Study of Platelet Glycoprotein Receptor Ib and IIb/IIIa Expression in Patients with Acute and Chronic Cerebrovascular Disease
por: Kraft, Peter, et al.
Publicado: (2015)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Pretreatment risk factors for parametrial involvement in FIGO stage IB1 cervical cancer
por: Yamazaki, Hiroyuki, et al.
Publicado: (2015)

An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome)
por: Pollock, Kari, et al.
Publicado: (2023)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB–IIIA Non-Small-Cell Lung Cancer Patients in Denmark
por: Uldbjerg, Ebbe Meldgaard, et al.
Publicado: (2023)

Risk factors for progressive sarcopenia 6 months after complete resection of lung cancer: what can thoracic surgeons do against sarcopenia?
por: Nagata, Masashi, et al.
Publicado: (2020)

Irritable bowel syndrome (IBS) among Lebanese adults: unidentified IBS and associated factors
por: Yazbeck, Gabriella, et al.
Publicado: (2023)

Gamma Radiation-Induced Damage in the Zinc Finger of the Transcription Factor IIIA
por: Zhang, XiaoHong, et al.
Publicado: (2016)

Desmoid‐type fibromatosis arising from thoracotomy incision
por: Samejima, Joji, et al.
Publicado: (2019)

Ionic liquids IIIA
por: Rogers, Robin D, et al.
Publicado: (2005)

Upregulation of epidermal growth factor receptor 4 in oral leukoplakia
por: Kobayashi, Hiroshi, et al.
Publicado: (2013)

Long-term follow-up of a consecutive cohort validating an epidermal growth factor receptor mutation as an independent risk factor for postoperative recurrence in lung adenocarcinoma
por: Matsumura, Yuki, et al.
Publicado: (2023)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial
por: Park, Cheol-Kyu, et al.
Publicado: (2022)

Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma
por: Saji, Hisashi, et al.
Publicado: (2017)

Optical fiber telecommunications IIIA
Publicado: (1997)

From hypertransaminasemia to mucopolysaccharidosis IIIA
por: Krawiec, Paulina, et al.
Publicado: (2014)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020)

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
por: Zhong, Wenzhao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qev1sspde163jqeq07f94gt9e7